Roche reports long-term data from diabetic macular oedema treatment trial
The study met all primary endpoints, confirming that Vabysmo was well-tolerated by DME patients.
18 July 2024
18 July 2024
The study met all primary endpoints, confirming that Vabysmo was well-tolerated by DME patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.